Lanier Biotherapeutics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

Lanier Biotherapeutics General Information

Description

Manufacturer of biotechnology products intended to support the selection, analysis, and synthesis of monoclonal antibodies. The company's products offer methods that obtain antibodies directly from the immune system of immunized mice and develop candidates for retinal, dermatological, and respiratory conditions, including anti-vascular endothelial growth factor and anti-interleukin monoclonal antibodies, enabling medical practitioners to access therapies with defined mechanisms of action.

Contact Information

Formerly Known As
Abeome
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • P.O. Box 1071
  • Jefferson, GA 30549
  • United States
+1 (678)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • P.O. Box 1071
  • Jefferson, GA 30549
  • United States
+1 (678)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lanier Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Later Stage VC Cancelled Generating Revenue
15. Merger/Acquisition 30-Sep-2021 Completed Generating Revenue
14. Later Stage VC 04-Aug-2021 Completed Generating Revenue
13. Grant 20-Sep-2016 Completed Generating Revenue
12. Later Stage VC 05-Jan-2016 Completed Generating Revenue
11. Grant 10-Feb-2014 Completed Generating Revenue
10. Grant 15-Mar-2013 Completed Generating Revenue
9. Grant 01-Nov-2010 Completed Generating Revenue
8. Grant 01-Jan-2010 $134K $2.1M Completed Generating Revenue
7. Later Stage VC 20-Jul-2008 $2.1M Completed Generating Revenue
To view Lanier Biotherapeutics’s complete valuation and funding history, request access »

Lanier Biotherapeutics Patents

Lanier Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025085538-A1 Alarmin binding molecules and treatment of cancer Inactive 17-Oct-2023
EP-4482522-A2 Anti-alarmin binding molecules and treatment of pneumonitis Pending 25-Feb-2022
EP-4482522-A4 Anti-alarmin binding molecules and treatment of pneumonitis Pending 25-Feb-2022
US-20250170238-A1 Anti-alarmin binding molecules and treatment of pneumonitis Pending 25-Feb-2022
WO-2023164649-A2 Anti-alarmin binding molecules and treatment of pneumonitis Inactive 25-Feb-2022 A61K39/3955
To view Lanier Biotherapeutics’s complete patent history, request access »

Lanier Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lanier Biotherapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advanced Technology Development Center Accelerator/Incubator Minority
Cato BioVentures Corporate Venture Capital Minority
Georgia Research Alliance Not-For-Profit Venture Capital Minority
Georgia Venture Partners Venture Capital Minority
National Heart, Lung, and Blood Institute Government
You’re viewing 5 of 6 investors. Get the full list »

Lanier Biotherapeutics FAQs

  • When was Lanier Biotherapeutics founded?

    Lanier Biotherapeutics was founded in 2000.

  • Where is Lanier Biotherapeutics headquartered?

    Lanier Biotherapeutics is headquartered in Jefferson, GA.

  • What is the size of Lanier Biotherapeutics?

    Lanier Biotherapeutics has 9 total employees.

  • What industry is Lanier Biotherapeutics in?

    Lanier Biotherapeutics’s primary industry is Biotechnology.

  • Is Lanier Biotherapeutics a private or public company?

    Lanier Biotherapeutics is a Private company.

  • What is Lanier Biotherapeutics’s current revenue?

    The current revenue for Lanier Biotherapeutics is .

  • How much funding has Lanier Biotherapeutics raised over time?

    Lanier Biotherapeutics has raised $4.9M.

  • Who are Lanier Biotherapeutics’s investors?

    Advanced Technology Development Center, Cato BioVentures, Georgia Research Alliance, Georgia Venture Partners, and National Heart, Lung, and Blood Institute are 5 of 6 investors who have invested in Lanier Biotherapeutics.

  • Who acquired Lanier Biotherapeutics?

    Lanier Biotherapeutics was acquired by Alloy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process